Theragnostic Radionuclide Pairs for Prostate Cancer Management: ⁶⁴Cu/⁶⁷Cu, Can Be a Budding Hot Duo

Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide. Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating PCa. In PCa patients, bone is one of the most co...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Anupriya Chhabra, Mathew L. Thakur
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-11-01
Saila:	Biomedicines
Gaiak:	prostate cancer theragnostic theragnostic radionuclide pairs radionuclide therapy bone metastases <sup>64</sup>Cu/<sup>67</sup>Cu
Sarrera elektronikoa:	https://www.mdpi.com/2227-9059/10/11/2787
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!